Maria Adelson1, Samuel Pannick2, James E East3, Peter Risby4, Peter Dawson1, Kevin J Monahan1,2. 1. Family History of Bowel Cancer Clinic, Department of Gastroenterology, West Middlesex University Hospital, London, UK. 2. Department of Gastroenterology, Family History of Bowel Cancer Clinic, West Middlesex University Hospital, London, UK. 3. Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford, UK. 4. Department of Clinical Genetics, Churchill Hospital, Oxford, UK.
Abstract
OBJECTIVE: To establish whether colorectal cancer patients in two centres in the UK are screened appropriately for Lynch syndrome, in accordance with current international guidance. DESIGN: Patients newly diagnosed with colorectal cancer over an 18-month period were identified from the UK National Bowel Cancer Audit Programme. Their records and management were reviewed retrospectively. SETTING: Two university teaching hospitals, Imperial College Healthcare and Oxford Radcliffe Hospitals NHS Trusts. OUTCOMES MEASURED: Whether patients were screened for Lynch syndrome-and the outcome of that evaluation, if it took place-were assessed from patients' clinical records. The age, tumour location and family history of screened patients were compared to those of unscreened patients. RESULTS: Five hundred and fifty three patients with newly diagnosed colorectal cancer were identified. Of these, 97 (17.5%) satisfied the revised Bethesda criteria, and should have undergone further assessment. There was no evidence that those guidelines had been contemporaneously applied to any patient. In practice, only 22 of the 97 (22.7%) eligible patients underwent evaluation. The results for 14 of those 22 (63.6%) supported a diagnosis of Lynch syndrome, but only nine of the 14 (64.3%) were referred for formal mismatch repair gene testing. No factors reliably predicted whether or not a patient would undergo Lynch syndrome screening. CONCLUSIONS: Colorectal teams in the UK do not follow international guidance identifying the patients who should be screened for Lynch syndrome. Patients and their families are consequently excluded from programmes reducing colorectal cancer incidence and mortality. Multidisciplinary teams should work with their local genetics services to develop reliable algorithms for patient screening and referral.
OBJECTIVE: To establish whether colorectal cancerpatients in two centres in the UK are screened appropriately for Lynch syndrome, in accordance with current international guidance. DESIGN:Patients newly diagnosed with colorectal cancer over an 18-month period were identified from the UK National Bowel Cancer Audit Programme. Their records and management were reviewed retrospectively. SETTING: Two university teaching hospitals, Imperial College Healthcare and Oxford Radcliffe Hospitals NHS Trusts. OUTCOMES MEASURED: Whether patients were screened for Lynch syndrome-and the outcome of that evaluation, if it took place-were assessed from patients' clinical records. The age, tumour location and family history of screened patients were compared to those of unscreened patients. RESULTS: Five hundred and fifty three patients with newly diagnosed colorectal cancer were identified. Of these, 97 (17.5%) satisfied the revised Bethesda criteria, and should have undergone further assessment. There was no evidence that those guidelines had been contemporaneously applied to any patient. In practice, only 22 of the 97 (22.7%) eligible patients underwent evaluation. The results for 14 of those 22 (63.6%) supported a diagnosis of Lynch syndrome, but only nine of the 14 (64.3%) were referred for formal mismatch repair gene testing. No factors reliably predicted whether or not a patient would undergo Lynch syndrome screening. CONCLUSIONS:Colorectal teams in the UK do not follow international guidance identifying the patients who should be screened for Lynch syndrome. Patients and their families are consequently excluded from programmes reducing colorectal cancer incidence and mortality. Multidisciplinary teams should work with their local genetics services to develop reliable algorithms for patient screening and referral.
Entities:
Keywords:
Colorectal Cancer; Colorectal Cancer Genes; Colorectal Carcinoma; Family Cancer; Inherited Cancers
Authors: Stuart R Cairns; John H Scholefield; Robert J Steele; Malcolm G Dunlop; Huw J W Thomas; Gareth D Evans; Jayne A Eaden; Matthew D Rutter; Wendy P Atkin; Brian P Saunders; Anneke Lucassen; Paul Jenkins; Peter D Fairclough; Christopher R J Woodhouse Journal: Gut Date: 2010-05 Impact factor: 23.059
Authors: Fay Kastrinos; Ewout W Steyerberg; Rowena Mercado; Judith Balmaña; Spring Holter; Steven Gallinger; Kimberly D Siegmund; James M Church; Mark A Jenkins; Noralane M Lindor; Stephen N Thibodeau; Lynn Anne Burbidge; Richard J Wenstrup; Sapna Syngal Journal: Gastroenterology Date: 2010-08-19 Impact factor: 22.682
Authors: Sining Chen; Wenyi Wang; Shing Lee; Khedoudja Nafa; Johanna Lee; Kathy Romans; Patrice Watson; Stephen B Gruber; David Euhus; Kenneth W Kinzler; Jeremy Jass; Steven Gallinger; Noralane M Lindor; Graham Casey; Nathan Ellis; Francis M Giardiello; Kenneth Offit; Giovanni Parmigiani Journal: JAMA Date: 2006-09-27 Impact factor: 56.272
Authors: Asad Umar; C Richard Boland; Jonathan P Terdiman; Sapna Syngal; Albert de la Chapelle; Josef Rüschoff; Richard Fishel; Noralane M Lindor; Lawrence J Burgart; Richard Hamelin; Stanley R Hamilton; Robert A Hiatt; Jeremy Jass; Annika Lindblom; Henry T Lynch; Païvi Peltomaki; Scott D Ramsey; Miguel A Rodriguez-Bigas; Hans F A Vasen; Ernest T Hawk; J Carl Barrett; Andrew N Freedman; Sudhir Srivastava Journal: J Natl Cancer Inst Date: 2004-02-18 Impact factor: 13.506
Authors: J Balmaña; F Balaguer; S Castellví-Bel; E W Steyerberg; M Andreu; X Llor; R Jover; A Castells; S Syngal Journal: J Med Genet Date: 2008-06-25 Impact factor: 6.318
Authors: Rowena C Mercado; Heather Hampel; Fay Kastrinos; Ewout Steyerberg; Judith Balmana; Elena Stoffel; David E Cohn; Floor J Backes; John L Hopper; Mark A Jenkins; Noralane M Lindor; Graham Casey; Robert Haile; Subha Madhavan; Albert de la Chapelle; Sapna Syngal Journal: Genet Med Date: 2012-03-08 Impact factor: 8.822
Authors: Kevin J Monahan; Nicola Bradshaw; Sunil Dolwani; Bianca Desouza; Malcolm G Dunlop; James E East; Mohammad Ilyas; Asha Kaur; Fiona Lalloo; Andrew Latchford; Matthew D Rutter; Ian Tomlinson; Huw J W Thomas; James Hill Journal: Gut Date: 2019-11-28 Impact factor: 23.059
Authors: Sophie Walton Bernstedt; Jan Björk; Kaisa Fritzell; Allan D Spigelman; Erik Björck; Ann-Sofie Backman Journal: Hered Cancer Clin Pract Date: 2021-02-12 Impact factor: 2.857